Digital Public Defence: Bart Maria Gilbert Baekelandt
Cand.med Bart Maria Gilbert Baekelandt at Institute of Clinical Medicine will be defending the thesis “Survival and patient reported outcome in surgically managed pancreatic and periampullary tumours” for the degree of PhD (Philosophiae Doctor).
Photo credit: Helene Dahl Jørum.
The public defence will be held as a video conference over Zoom.
The digital trial lecture will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Due to copyright reasons, an electronic copy of the thesis must be ordered from the faculty. In order for the faculty to have time to process the order, it must be received by the faculty no later than 2 days prior to the public defence. Orders received later than 2 days before the defence will not be processed. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Digital Trial Lecture – time and place
- First opponent: Senior Consultant Britt-Marie Karlson, Akademiska sjukhuset, Uppsala
- Second opponent: Senior Consultant Jon-Helge Angelsen, Haukeland University hospital
- Third member and chair of the evaluation committee: Professor II John Terje Geitung, University of Oslo
Chair of the Defence
Professor II Lars Nordsletten, University of Oslo
Professor II Trond A. Buanes, University of Oslo
The present PhD-thesis investigates opportunities for improving management of surgically treated pancreatic cancer patients by incorporating patients’ experience. The aim was to explore the putative prognostic value of patient reported outcome (PRO), the effects of complications on longitudinal PRO, and the value of PACADI, a short, patient-derived and disease-specific PRO measure.
Preoperative cognitive function was independently associated with survival, with 10 months median survival for patients with self-reported cognitive impairment and 21 months for patients reporting normal cognition (p<.001).
No significant difference in PRO was found at 3 and 6 months after surgery between patients with or without complications, suggesting limited negative long-term effect of complications.
The PACADI score has prognostic value and shows better psychometric performance compared with two widely used generic questionnaires.
PRO has prognostic value and should be part of preoperative assessment. PRO also enables monitoring of treatment effects, potentially improving outcome. Because of its feasibility and good psychometric scores, PACADI should be used in patients with pancreatic cancer.
Contact the research support staff.